According to Zacks, “Applied DNA Sciences, Inc. provides proprietary DNA-embedded biotechnology security solutions, using non-human DNA, that verify authenticity and protect corporate and government agencies from counterfeiting, fraud, piracy, product diversion, identity theft and unauthorized intrusion. They develop, market, and sub-license DNA security systems, supply-chain management systems and anti-counterfeit solutions. Applied DNA Sciences has an exclusive licensing and partnership agreement covering North America and Europe with Biowell Technology, Inc. of Taiwan. “
APDN has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective (down from $18.00) on shares of Applied DNA Sciences in a research report on Monday, January 11th. Roth Capital initiated coverage on shares of Applied DNA Sciences in a report on Friday, February 12th. They issued a “buy” rating and a $24.00 target price for the company.
Applied DNA Sciences (NASDAQ:APDN) last announced its quarterly earnings data on Wednesday, February 10th. The technology company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.02). Applied DNA Sciences had a negative net margin of 672.79% and a negative return on equity of 179.48%. The firm had revenue of $1.62 million during the quarter, compared to analysts’ expectations of $1.40 million. Analysts forecast that Applied DNA Sciences will post -0.33 EPS for the current year.
A number of large investors have recently modified their holdings of APDN. Orion Portfolio Solutions LLC acquired a new stake in Applied DNA Sciences during the 4th quarter worth $65,000. Golden Green Inc. acquired a new stake in Applied DNA Sciences during the 4th quarter worth $70,000. Squarepoint Ops LLC acquired a new stake in Applied DNA Sciences during the 3rd quarter worth $78,000. Schonfeld Strategic Advisors LLC acquired a new stake in Applied DNA Sciences during the 3rd quarter worth $84,000. Finally, GSA Capital Partners LLP acquired a new stake in Applied DNA Sciences during the 4th quarter worth $186,000. Hedge funds and other institutional investors own 7.04% of the company’s stock.
Applied DNA Sciences Company Profile
Applied DNA Sciences, Inc develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia.
See Also: Accumulation/Distribution
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.